Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis.
Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.
['Puing|Alfredo G|AG|', 'Epstein|David J|DJ|', 'Banaei|Niaz|N|', 'Subramanian|Aruna K|AK|', 'Liu|Anne Y|AY|']
D006801:Humans D016867:Immunocompromised Host D009617:Nocardia Infections D011010:Pneumocystis D045363:Pneumocystis carinii D011020:Pneumonia, Pneumocystis D012189:Retrospective Studies
immunocompromised trimethoprim/sulfamethoxazole Pneumocystis jirovecii Nocardia bacteria drug allergy fungi respiratory infections sulfa